Psarova V. G.


About the author:

Psarova V. G.



Type of article:

Scentific article


The purpose of the work was to assess the factors that are fundamental in the formation of a group of hypertensive patients with different body mass and type 2 diabetes mellitus. 340 patients with AH aged 45 to 55 who gave informed written consent to participate in the study and met the inclusion criteria were examined. Group 1 consisted of 200 patients with AH and obesity I–II classes, group 2 – 50 patients with AH and normal body weight, group 3 – 50 patients with AH and overweight, 4 group – 40 patients with AH, obesity I–II classes and type 2 diabetes mellitus. Analysis included 64 indicators. In the factor analysis of the group of hypertensive patients 4 factors were found. Those factors explained 24,86% of the variability of the indicators. The data of the logistic regression method showed that the formation of a group of hypertensive patients with different body weight and type 2 diabetes mellitus was influenced by anthropometric indicators (BMI (р = = 0,0045)), metabolic indicators (HOMA index (р = 0,0040), adiponectin (р = 0, 0117), glycosylated hemoglobin (p = 0.0411)), hemodynamic parameters (mean BP (p = 0.0182)), RAAS activity (aldosterone (р = 0,0067)), antioxidant defense system performance (general antioxidant protection (р = 0,0489)), systolic (of course the systolic diameter of the left ventricle (р = 0,0044)) and diastolic cardiac function (MV A (р = 0,0381)), as well as ADIPOQ genetic polymorphism (р = 0,0073).


hypertension, obesity, diabetes mellitus, factor analysis, logistic regression.


  1. Markel AL. Genetika i patofiziologiya nizkoreninovoy arterialnoy gipertonii. Vavilovskiy zhurnal genetiki i selektsii. 2018;22(8):1000-8. DOI: 10.18699/VJ18,443. [іn Russian].
  2. Elijovich F, Weinberger MH, Anderson CAM, Appel LJ, Bursztyn M, Cook NR, et al. On behalf of the American Heart Association Professional and Public Education Committee of the Council on Hypertension; Council on Genomic and Precision Medicine; and Stroke Council. Salt sensitivity of blood pressure: a scientific statement from the American Heart Association. [published online ahead of print July 21, 2016]. Hypertension. DOI: 10.1161/HYP.0000000000000047
  3. Bilovol OM, Shalimova AS, Kochuieva MM. Komorbidnist hipertonichnoi khvoroby i tsukrovoho diabetu 2 typu – aktualna problema suchasnoi medytsyny. Ukrainskyi terapevtychnyi journal. 2014;1:11-7. [in Ukrainian].
  4. Balabolkina MI, redactor. Insulinovaya rezistentnost: molekulyarno-geneticheskie mehanizmyi razvitiya, diagnostika i korrektsiya pri saharnom diabete tip 2. Moskva; 2007. 36 s. [in Russian].
  5. Mayorov AYu. Insulinorezistentnost v patogeneze saharnogo diabeta 2 tipa. Saharnyiy diabet. 2011;1:35-43. [in Russian].
  6. Provorotov VM, Drobyisheva ES, Bunina MN. Fenomen insulinorezistentnosti: mehanizmyi formirovaniya, vozmozhnosti diagnostiki i sposobyi korrektsii na sovremennom etape. Novyie Sankt-Peterburgskie vrachebnyie vedomosti. 2014;1:82-5. [in Russian].
  7. Kumar S, O’Rahylly S. Insulin Resistance. Insulin action and its disturbances in disease. Chichester; 2005. 599 p.
  8. Shalimova A, Fadieienko G, Kolesnikova O, Isayeva A, Zlatkina V, Nemtsova V, et al. The role of genetic polymorphism in the formation of arterial hypertension, type 2 diabetes and their comorbidity. Current Pharmaceutical Design. 2019;25:218-27.
  9. Whitehead JP, Richards AA, Hickman IJ. Adiponectin – a key adipokine in the metabolic syndrome. Diab, Obes, Metabol. 2006;8:264-80.
  10. Lin CH, Ho CY, Liu CS. Influence of Adiponectin Gene Polymorphisms on Adiponectin Serum Level and Insulin Resistance Index in Taiwanese Metabolic Syndrome Patients. Chin J Physiol. 2012;55(6):405-11.
  11. Siitonen N, Pulkkinen L, Lindström J. Association of ADIPOQ gene variants with body weight, type 2 diabetes and serum adiponectin concentrations: the Finnish Diabetes Prevention Study. BMC Med Genet. 2011;10:12-5.
  12. Aileen JM, Edward PF, Ronald KJ. Human Insulin Receptor Substrate-1 (IRS-1) Polymorphism G972R Causes IRS-1 to Associate with the Insulin Receptor and Inhibit Receptor Autophosphorylation. J Biol Chem. 2005;280:6441-6.
  13. Rung J, Cauchi S, Albrechtsen A, Shen L, Rocheleau G, Cavalcanti-Proença C, et al. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet. 2009;41(10):1110-5.
  14. Kilpeläinen TO, Zillikens MC, Stančákova A, Finucane FM, Ried JS, Langenberg C, et al. Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat Genet. 2011;43(8):753-60.

Publication of the article:

«Bulletin of problems biology and medicine» Issue 4 Part 2 (154), 2019 year, 188-192 pages, index UDK 616.12-008.33:[616.379-008.64+613.25]